<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00513695</url>
  </required_header>
  <id_info>
    <org_study_id>6488</org_study_id>
    <secondary_id>NCI-2010-00607</secondary_id>
    <nct_id>NCT00513695</nct_id>
    <nct_alias>NCT00831584</nct_alias>
  </id_info>
  <brief_title>Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer</brief_title>
  <official_title>A Phase II Study Evaluating the Safety and Efficacy of Sunitinib Maleate in Combination With Weekly Paclitaxel Followed by Doxorubicin and Daily Oral Cyclophosphamide Plus G-CSF as Neoadjuvant Chemotherapy for Locally Advanced or Inflammatory Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well giving sunitinib malate together with paclitaxel,
      doxorubicin hydrochloride, and cyclophosphamide before surgery works in treating patients
      with stage IIB-IIIC breast cancer. Sunitinib malate may stop the growth of tumor cells by
      blocking some of the enzymes needed for cell growth or by blocking blood flow to the tumor.
      Drugs used in chemotherapy, such as paclitaxel, doxorubicin hydrochloride, and
      cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing
      the cells or by stopping them from dividing. Giving sunitinib malate together with
      combination chemotherapy before surgery may make the tumor smaller and reduce the amount of
      normal tissue that needs to be removed
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I.To assess the microscopic pathologic complete response rate (pCR) in patients treated with
      a two part, neoadjuvant regimen consisting of daily oral sunitinib with weekly IV paclitaxel
      for 12 weeks followed by weekly doxorubicin and daily oral cyclophosphamide given with
      filgrastim (G-CSF) support for 15 weeks.

      SECONDARY OBJECTIVES:

      I. To assess the association between microscopic pCR and clinical complete response rate at
      the primary tumor site.

      II. To assess the relapse rate, overall and disease-free survival in patients with breast
      cancer treated with neoadjuvant chemotherapy consisting of daily oral sunitinib with weekly
      IV paclitaxel for 12 weeks followed weekly doxorubicin and daily oral cyclophosphamide given
      with G-CSF support for 15 weeks.

      III. To assess the toxicity associated with these regimens. IV. To explore the relationship
      between planned correlative laboratory and clinical studies and indicators of efficacy such
      as pathologic response, clinical response and relapse.

      OUTLINE:

      Patients receive neoadjuvant chemotherapy comprising sunitinib malate orally (PO) once daily
      and paclitaxel intravenously (IV) over 1 hour once weekly for 8-12 weeks in the absence of
      disease progression or unacceptable toxicity. Beginning within 3 weeks of completion of
      sunitinib malate and paclitaxel, patients receive doxorubicin IV once weekly for 15 weeks,
      cyclophosphamide PO once daily for 15 weeks, and filgrastim subcutaneously (SC) on days 2-7
      for 16 weeks in the absence of disease progression or unacceptable toxicity. Beginning 3-6
      weeks after completion of chemotherapy, patients undergo surgery.

      After completion of study treatment, patients are followed up every 3 months for 2 years,
      every 6 months for 3 years, and then annually thereafter.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>June 2007</start_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Microscopic Pathologic CR (pCR) Rate</measure>
    <time_frame>At the time of surgery</time_frame>
    <description>Defined as no evidence of microscopic invasive tumor present at primary tumor site in the surgical specimen and calculated with exact 90% binomial confidence interval.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Complete Response and Correlation With Plasma VEGF, Soluble VCAM (sVCAM), and Circulating Endothelial Cells (CECs) Levels</measure>
    <time_frame>At baseline, after week 12 of therapy, and prior to surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse Rate</measure>
    <time_frame>Up to two years</time_frame>
    <description>Cumulative incidence rate of relapse, assessed at two years. Death is considered a competing risk.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Disease Progression</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Median time to disease progression, at two years, as defined by clear increase in disease sites present at registration or development of new disease sites.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Kaplan-Meier estimate from the start of protocol therapy until the date of death from any cause or the last date the patient was known to be alive, assessed at two years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and Percent of Subjects Reporting Adverse Events</measure>
    <time_frame>28 days after the last dose of study drug</time_frame>
    <description>See Adverse Events section for more details.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">68</enrollment>
  <condition>Inflammatory Breast Cancer</condition>
  <condition>Male Breast Cancer</condition>
  <condition>Stage II Breast Cancer</condition>
  <condition>Stage IIIA Breast Cancer</condition>
  <condition>Stage IIIB Breast Cancer</condition>
  <condition>Stage IIIC Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment (neoadjuvant chemotherapy before surgery)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive neoadjuvant chemotherapy comprising sunitinib malate PO once daily and paclitaxel IV over 1 hour once weekly for 8-12 weeks in the absence of disease progression or unacceptable toxicity. Beginning within 3 weeks of completion of sunitinib malate and paclitaxel, patients receive doxorubicin IV once weekly for 15 weeks, cyclophosphamide PO once daily for 15 weeks, and filgrastim SC on days 2-7 for 16 weeks in the absence of disease progression or unacceptable toxicity. Beginning 3-6 weeks after completion of chemotherapy, patients undergo surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sunitinib malate</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (neoadjuvant chemotherapy before surgery)</arm_group_label>
    <other_name>SU11248</other_name>
    <other_name>sunitinib</other_name>
    <other_name>Sutent</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (neoadjuvant chemotherapy before surgery)</arm_group_label>
    <other_name>Anzatax</other_name>
    <other_name>Asotax</other_name>
    <other_name>TAX</other_name>
    <other_name>Taxol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (neoadjuvant chemotherapy before surgery)</arm_group_label>
    <other_name>ADM</other_name>
    <other_name>ADR</other_name>
    <other_name>Adria</other_name>
    <other_name>Adriamycin PFS</other_name>
    <other_name>Adriamycin RDF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (neoadjuvant chemotherapy before surgery)</arm_group_label>
    <other_name>CPM</other_name>
    <other_name>CTX</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Endoxan</other_name>
    <other_name>Endoxana</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Treatment (neoadjuvant chemotherapy before surgery)</arm_group_label>
    <other_name>G-CSF</other_name>
    <other_name>Neupogen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>therapeutic conventional surgery</intervention_name>
    <description>Undergo surgery</description>
    <arm_group_label>Treatment (neoadjuvant chemotherapy before surgery)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (neoadjuvant chemotherapy before surgery)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>flow cytometry</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (neoadjuvant chemotherapy before surgery)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Be informed of the investigational nature of the study and all pertinent aspects of
             the trial and must sign and give written consent in accordance with institutional and
             federal guidelines

          -  Have a histologically-confirmed diagnosis of breast cancer that is locally advanced or
             inflammatory; inflammatory breast cancer is defined as erythema and peau d'orange
             involving half or more of the breast with a histologic diagnosis of breast cancer; the
             finding of focal dermal lymphatic involvement on histology does not constitute
             inflammatory breast cancer

          -  Have selected stage IIB (T3, N0, M0) or IIIA (T3, N1-2, M0 or T0-2, N2, M0) disease
             judged primarily unresectable by an experienced breast surgeon or otherwise deemed
             appropriate candidates for neoadjuvant treatment or stage IIIB (T4, any N, M0) or
             stage IIIC (any T, N3, M0) disease

          -  Patients must have a performance status of 0-2 by Zubrod criteria

          -  Absolute neutrophil count (ANC) &gt;= 1,500 cells/mm^3

          -  Platelet count &gt;= 100,000 cells/mm^3

          -  Serum creatinine =&lt; 1.5 x institutional upper limit of normal (IULN)

          -  Bilirubin =&lt; 2.0

          -  Serum glutamic oxaloacetic transaminase (SGOT)/serum glutamic pyruvic transaminase
             (SGPT)/alkaline phosphatase =&lt; 2.0 x IULN

          -  Have a multi gated acquisition scan (MUGA) or echocardiogram scan performed within 3
             months prior to enrollment and have a left ventricular ejection fraction (LVEF) %
             greater than the institutional lower limit of normal

          -  Be willing and able to comply with scheduled visits, treatment plan, laboratory tests
             and other trial procedures

        Exclusion Criteria:

          -  Have evidence of distant metastases

          -  Have tumors that overexpress human epidermal growth factor receptor 2 (HER2)/neu as
             evidenced by 3+ staining by immunohistochemistry or gene amplification by fluorescent
             in situ hybridization (FISH)

          -  Have received any prior chemotherapy or hormonal therapy for breast cancer

          -  Have received prior radiation therapy or prior definitive surgery for breast cancer

          -  Have a clinical diagnosis of congestive heart failure or angina pectoris or any of the
             following within the 6 months prior to study drug administration:, myocardial
             infarction, coronary/peripheral artery bypass graft, cerebrovascular accident or
             transient ischemic attack, or pulmonary embolism

          -  Have ongoing cardiac dysrhythmias of National Cancer Institute (NCI) Common Toxicity
             Criteria for Adverse Events (CTCAE) version 3.0 grade &gt;= 2

          -  Have uncontrolled hypertension (&gt;150/100 mm Hg despite optimal medical therapy)

          -  Have pre-existing thyroid abnormality with thyroid function that cannot be maintained
             in the normal range with medication

          -  Have a known, active infection

          -  Have any prior malignancy except for adequately treated basal cell or squamous cell
             skin cancer, any in situ cancer, adequately treated stage I or II cancer from which
             the patient is currently in complete remission or any other cancer from which the
             patient has been disease-free for 5 years

          -  Human immunodeficiency virus (HIV) positive

          -  Are receiving or planning to receive any concurrent anticancer therapy while receiving
             protocol treatment

          -  Are receiving or planning to receive concurrent treatment on another clinical trial
             (supportive care trials or non-treatment trials, e.g. quality of life (QOL) are
             allowed; participation in the companion imaging trial, dynamic contrast
             enhanced-magnetic resonance imaging (DCE-MRI) and fludeoxyglucose F 18 positron
             emission tomography (FDG PET) with Kinetic Analysis to Monitor Breast Cancer Response
             to Neoadjuvant Sunitinib and Metronomic Chemotherapy is also allowed)

          -  Be pregnant or breast feeding; female subjects must be surgically sterile or be
             postmenopausal, or must agree to use effective contraception during the period of
             therapy; all female subjects with reproductive potential must have a negative
             pregnancy test (serum or urine) prior to enrollment; male subjects must be surgically
             sterile or must agree to use effective contraception during the period of therapy; the
             definition of effective contraception will be based on the judgment of the principal
             investigator or a designated associate

          -  Have other severe acute or chronic medical or psychiatric condition or laboratory
             abnormality that may increase the risk associated with study participation or study
             drug administration, or may interfere with the interpretation of study results, and in
             the judgment of the investigator would make the subject inappropriate for entry into
             this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer Specht</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Anchorage Oncology Centre</name>
      <address>
        <city>Anchorage</city>
        <state>Alaska</state>
        <zip>99508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Katmai Oncology Group</name>
      <address>
        <city>Anchorage</city>
        <state>Alaska</state>
        <zip>99508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arizona Cancer Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724-5024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Luke's Mountain States Tumor Institute</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skagit Valley Hospital</name>
      <address>
        <city>Mount Vernon</city>
        <state>Washington</state>
        <zip>98273</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Olympic Medical Center</name>
      <address>
        <city>Port Angeles</city>
        <state>Washington</state>
        <zip>98362</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 8, 2007</study_first_submitted>
  <study_first_submitted_qc>August 8, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 9, 2007</study_first_posted>
  <results_first_submitted>March 24, 2017</results_first_submitted>
  <results_first_submitted_qc>March 24, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 10, 2017</results_first_posted>
  <last_update_submitted>May 15, 2017</last_update_submitted>
  <last_update_submitted_qc>May 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>Jennifer Specht</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Breast Neoplasms, Male</mesh_term>
    <mesh_term>Inflammatory Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Sunitinib</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment (Neoadjuvant Chemotherapy Before Surgery)</title>
          <description>Patients receive neoadjuvant chemotherapy comprising sunitinib malate PO once daily and paclitaxel IV over 1 hour once weekly for 8-12 weeks in the absence of disease progression or unacceptable toxicity. Beginning within 3 weeks of completion of sunitinib malate and paclitaxel, patients receive doxorubicin IV once weekly for 15 weeks, cyclophosphamide PO once daily for 15 weeks, and filgrastim SC on days 2-7 for 16 weeks in the absence of disease progression or unacceptable toxicity. Beginning 3-6 weeks after completion of chemotherapy, patients undergo surgery.
sunitinib malate: Given PO
paclitaxel: Given IV
doxorubicin hydrochloride: Given IV
cyclophosphamide: Given PO
filgrastim: Given SC
therapeutic conventional surgery: Undergo surgery
laboratory biomarker analysis: Correlative studies
flow cytometry: Correlative studies</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="68"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="63"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Discontinued therapy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Progression prior to surgery</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment (Neoadjuvant Chemotherapy Before Surgery)</title>
          <description>Patients receive neoadjuvant chemotherapy comprising sunitinib malate PO once daily and paclitaxel IV over 1 hour once weekly for 8-12 weeks in the absence of disease progression or unacceptable toxicity. Beginning within 3 weeks of completion of sunitinib malate and paclitaxel, patients receive doxorubicin IV once weekly for 15 weeks, cyclophosphamide PO once daily for 15 weeks, and filgrastim SC on days 2-7 for 16 weeks in the absence of disease progression or unacceptable toxicity. Beginning 3-6 weeks after completion of chemotherapy, patients undergo surgery.
sunitinib malate: Given PO
paclitaxel: Given IV
doxorubicin hydrochloride: Given IV
cyclophosphamide: Given PO
filgrastim: Given SC
therapeutic conventional surgery: Undergo surgery
laboratory biomarker analysis: Correlative studies
flow cytometry: Correlative studies</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="68"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50" lower_limit="33" upper_limit="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Microscopic Pathologic CR (pCR) Rate</title>
        <description>Defined as no evidence of microscopic invasive tumor present at primary tumor site in the surgical specimen and calculated with exact 90% binomial confidence interval.</description>
        <time_frame>At the time of surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Neoadjuvant Chemotherapy Before Surgery)</title>
            <description>Patients receive neoadjuvant chemotherapy comprising sunitinib malate PO once daily and paclitaxel IV over 1 hour once weekly for 8-12 weeks in the absence of disease progression or unacceptable toxicity. Beginning within 3 weeks of completion of sunitinib malate and paclitaxel, patients receive doxorubicin IV once weekly for 15 weeks, cyclophosphamide PO once daily for 15 weeks, and filgrastim SC on days 2-7 for 16 weeks in the absence of disease progression or unacceptable toxicity. Beginning 3-6 weeks after completion of chemotherapy, patients undergo surgery.
sunitinib malate: Given PO
paclitaxel: Given IV
doxorubicin hydrochloride: Given IV
cyclophosphamide: Given PO
filgrastim: Given SC
therapeutic conventional surgery: Undergo surgery
laboratory biomarker analysis: Correlative studies
flow cytometry: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Microscopic Pathologic CR (pCR) Rate</title>
          <description>Defined as no evidence of microscopic invasive tumor present at primary tumor site in the surgical specimen and calculated with exact 90% binomial confidence interval.</description>
          <units>percent of evaluable participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27" lower_limit="18" upper_limit="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Complete Response and Correlation With Plasma VEGF, Soluble VCAM (sVCAM), and Circulating Endothelial Cells (CECs) Levels</title>
        <time_frame>At baseline, after week 12 of therapy, and prior to surgery</time_frame>
        <population>Data not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Neoadjuvant Chemotherapy Before Surgery)</title>
            <description>Patients receive neoadjuvant chemotherapy comprising sunitinib malate PO once daily and paclitaxel IV over 1 hour once weekly for 8-12 weeks in the absence of disease progression or unacceptable toxicity. Beginning within 3 weeks of completion of sunitinib malate and paclitaxel, patients receive doxorubicin IV once weekly for 15 weeks, cyclophosphamide PO once daily for 15 weeks, and filgrastim SC on days 2-7 for 16 weeks in the absence of disease progression or unacceptable toxicity. Beginning 3-6 weeks after completion of chemotherapy, patients undergo surgery.
sunitinib malate: Given PO
paclitaxel: Given IV
doxorubicin hydrochloride: Given IV
cyclophosphamide: Given PO
filgrastim: Given SC
therapeutic conventional surgery: Undergo surgery
laboratory biomarker analysis: Correlative studies
flow cytometry: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Complete Response and Correlation With Plasma VEGF, Soluble VCAM (sVCAM), and Circulating Endothelial Cells (CECs) Levels</title>
          <population>Data not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relapse Rate</title>
        <description>Cumulative incidence rate of relapse, assessed at two years. Death is considered a competing risk.</description>
        <time_frame>Up to two years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Neoadjuvant Chemotherapy Before Surgery)</title>
            <description>Patients receive neoadjuvant chemotherapy comprising sunitinib malate PO once daily and paclitaxel IV over 1 hour once weekly for 8-12 weeks in the absence of disease progression or unacceptable toxicity. Beginning within 3 weeks of completion of sunitinib malate and paclitaxel, patients receive doxorubicin IV once weekly for 15 weeks, cyclophosphamide PO once daily for 15 weeks, and filgrastim SC on days 2-7 for 16 weeks in the absence of disease progression or unacceptable toxicity. Beginning 3-6 weeks after completion of chemotherapy, patients undergo surgery.
sunitinib malate: Given PO
paclitaxel: Given IV
doxorubicin hydrochloride: Given IV
cyclophosphamide: Given PO
filgrastim: Given SC
therapeutic conventional surgery: Undergo surgery
laboratory biomarker analysis: Correlative studies
flow cytometry: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Relapse Rate</title>
          <description>Cumulative incidence rate of relapse, assessed at two years. Death is considered a competing risk.</description>
          <units>probability of relapse</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.215" lower_limit="0.125" upper_limit="0.322"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Disease Progression</title>
        <description>Median time to disease progression, at two years, as defined by clear increase in disease sites present at registration or development of new disease sites.</description>
        <time_frame>Up to 2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Neoadjuvant Chemotherapy Before Surgery)</title>
            <description>Patients receive neoadjuvant chemotherapy comprising sunitinib malate PO once daily and paclitaxel IV over 1 hour once weekly for 8-12 weeks in the absence of disease progression or unacceptable toxicity. Beginning within 3 weeks of completion of sunitinib malate and paclitaxel, patients receive doxorubicin IV once weekly for 15 weeks, cyclophosphamide PO once daily for 15 weeks, and filgrastim SC on days 2-7 for 16 weeks in the absence of disease progression or unacceptable toxicity. Beginning 3-6 weeks after completion of chemotherapy, patients undergo surgery.
sunitinib malate: Given PO
paclitaxel: Given IV
doxorubicin hydrochloride: Given IV
cyclophosphamide: Given PO
filgrastim: Given SC
therapeutic conventional surgery: Undergo surgery
laboratory biomarker analysis: Correlative studies
flow cytometry: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Disease Progression</title>
          <description>Median time to disease progression, at two years, as defined by clear increase in disease sites present at registration or development of new disease sites.</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not reached because not enough progression events.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Kaplan-Meier estimate from the start of protocol therapy until the date of death from any cause or the last date the patient was known to be alive, assessed at two years.</description>
        <time_frame>Up to 2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Neoadjuvant Chemotherapy Before Surgery)</title>
            <description>Patients receive neoadjuvant chemotherapy comprising sunitinib malate PO once daily and paclitaxel IV over 1 hour once weekly for 8-12 weeks in the absence of disease progression or unacceptable toxicity. Beginning within 3 weeks of completion of sunitinib malate and paclitaxel, patients receive doxorubicin IV once weekly for 15 weeks, cyclophosphamide PO once daily for 15 weeks, and filgrastim SC on days 2-7 for 16 weeks in the absence of disease progression or unacceptable toxicity. Beginning 3-6 weeks after completion of chemotherapy, patients undergo surgery.
sunitinib malate: Given PO
paclitaxel: Given IV
doxorubicin hydrochloride: Given IV
cyclophosphamide: Given PO
filgrastim: Given SC
therapeutic conventional surgery: Undergo surgery
laboratory biomarker analysis: Correlative studies
flow cytometry: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Kaplan-Meier estimate from the start of protocol therapy until the date of death from any cause or the last date the patient was known to be alive, assessed at two years.</description>
          <units>survival probability</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.875" lower_limit="0.798" upper_limit="0.960"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number and Percent of Subjects Reporting Adverse Events</title>
        <description>See Adverse Events section for more details.</description>
        <time_frame>28 days after the last dose of study drug</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Neoadjuvant Chemotherapy Before Surgery)</title>
            <description>Patients receive neoadjuvant chemotherapy comprising sunitinib malate PO once daily and paclitaxel IV over 1 hour once weekly for 8-12 weeks in the absence of disease progression or unacceptable toxicity. Beginning within 3 weeks of completion of sunitinib malate and paclitaxel, patients receive doxorubicin IV once weekly for 15 weeks, cyclophosphamide PO once daily for 15 weeks, and filgrastim SC on days 2-7 for 16 weeks in the absence of disease progression or unacceptable toxicity. Beginning 3-6 weeks after completion of chemotherapy, patients undergo surgery.
sunitinib malate: Given PO
paclitaxel: Given IV
doxorubicin hydrochloride: Given IV
cyclophosphamide: Given PO
filgrastim: Given SC
therapeutic conventional surgery: Undergo surgery
laboratory biomarker analysis: Correlative studies
flow cytometry: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Number and Percent of Subjects Reporting Adverse Events</title>
          <description>See Adverse Events section for more details.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Treatment (Neoadjuvant Chemotherapy Before Surgery)</title>
          <description>Patients receive neoadjuvant chemotherapy comprising sunitinib malate PO once daily and paclitaxel IV over 1 hour once weekly for 8-12 weeks in the absence of disease progression or unacceptable toxicity. Beginning within 3 weeks of completion of sunitinib malate and paclitaxel, patients receive doxorubicin IV once weekly for 15 weeks, cyclophosphamide PO once daily for 15 weeks, and filgrastim SC on days 2-7 for 16 weeks in the absence of disease progression or unacceptable toxicity. Beginning 3-6 weeks after completion of chemotherapy, patients undergo surgery.
sunitinib malate: Given PO
paclitaxel: Given IV
doxorubicin hydrochloride: Given IV
cyclophosphamide: Given PO
filgrastim: Given SC
therapeutic conventional surgery: Undergo surgery
laboratory biomarker analysis: Correlative studies
flow cytometry: Correlative studies</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia (ANC)</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Leucopenia</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ALT elevation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Sensory Neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Mucositis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Nail changes</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia (ANC)</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Leucopenia</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Heartburn</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ALT elevation</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Sensory Neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mood alteration</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Mucositis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Nail changes</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jennifer Specht, MD</name_or_title>
      <organization>Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium</organization>
      <phone>(206) 288-6889</phone>
      <email>jspecht@uw.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

